Fig. 3

Inhibition of TGFβ/Smad23 pathway enhances the sensitivity of ESCC cells to cisplatinum A Western blotting detected the expression of TGFβ/Smad2/3 pathway proteins of EC109 and EC9706 cells in the 4ug/ml cisplatin medium or M2-CM and cisplatin mixed medium. B Expression of Smad2/3 pathway proteins in tumor tissues of nude mice. C, D CCK-8 detected the cisplatin IC50 value changes of EC109 and EC9706 cells after pretreated with M2-CM or M2-CM + SB431542 for 24 h. E FCM assay was used to analyze the apoptosis rates of EC109 and EC9706 cells in 4ug/ml cisplatin medium after M2-CM or M2-CM + SB431542 pretreatment for 24 h. F, G qRT-PCR and western blot were used to verify the TGFβR1knockdown efficiency in EC109 cells. H CCK-8 experiment analyzed the cisplatin IC50 values of shTGFβR1 EC109 and shNC EC109 cells after pretreated with M2-CM for 24 h. I Plate colony-formation experiments were used to detect the proliferation abilities of shTGFβR1 and shNC EC109 cells in cisplatin and M2-CM mixed medium. J FCM analyzed the apoptosis rates of shTGFβR1 EC109 and shNC EC109 in 4ug/ml cisplatin medium and M2-CM mixed medium. All experiments were repeated three times and expressed as mean ± SD, ns represents no significant difference, *P < 0.05, **P < 0.01, ***P < 0.001